Table 1.
Demographic data.
| A | No OA | ASA | ASA + Clopidogrel | NOACs |
| Total number | 5 | 8 | 10 | 7 |
| Male/Female | 4/1 | 6/2 | 9/1 | 5/2 |
| Mean age ± SD (years) | 26.0 ± 3.8 | 71.8 ± 5.9 | 71.5 ± 6.4 | 67.0 ± 8.6 |
| moking (number of subjects) | 0 | 1 | 4 | 0 |
| Diabetes Mellitus (number of subjects) | 0 | 4 | 2 | 1 |
| B | No DM(No OA) | T1D(No OA) | T2D(No OA) | |
| Total number | 8 | 6 | 10 | |
| Male/Female | 4/4 | 4/2 | 1/9 | |
| Mean age ± SD (years) | 30.75 ± 3.99 | 39.0 ± 5.88 | 62.4 ± 18.55 | |
| BMI (kg/m²) | 20.87 ± 2.50 | 26.34 ± 4.92 | 40.7 ± 15.16 | |
| Blood glucoseat the time of blood collection (mg/dL) | 98.75 ± 5.58 | 126.84 ± 37.74 | 122.2 ± 31.58 |
Patient demographics of different subject groups included in (A) oral anticoagulation (OA) experiments to assess the effects of three of the most widely used oral blood anticoagulants: group 1, acetylsalicylic acid (ASA) (100 mg/day), group 2, a combination of ASA + clopidogrel (Plavix) (100 mg + 75 mg/day), and group 3, nonvitamin K antagonist oral anticoagulants (NOACs) (e.g., Apixaban and Rivaroxaban) (dose was dependent on the pathology and drug type). All subjects were under a consistent blood anticoagulation regime in the past 6 months and (B) diabetes mellitus (DM) experiments, further differentiated into type 1 (T1D) and type 2 (T2D) diabetes, in order to assess the effect of DM independently of OA use. Subjects had a clinical diagnosis of DM for longer than one year prior to initiation of the study. BMI = body mass index and SD = standard deviation.